The aim of this study was to examine GFAP and NfL levels in CSF and plasma in various stages of the clinical AD continuum and to investigate the predictive value of these blood biomarkers in combination with well-established risk factors in relation to clinical diagnosis and amyloid positivity. The gene discussed is GFAP; the disease is Alzheimer disease.